Professional Resources
Here are educational tools to maximize the benefits of Campath® (alemtuzumab) treatment, including slide kits and support resources.
CLL Slide Kit, "A Contemporary Perspective on Diagnosis and Treatment" Part 1: Diagnosis, Staging, and Prognosis
CLL Slide Kit Part 1 Diagnosis, Staging, Prognosis
CLL Slide Kit, "A Contemporary Perspective on Diagnosis and Treatment"
Part 2: Pharmacotherapeutic Options
CLL Slide Kit Part 2 Pharmacotherapeutic Options
Bayer HealthCare Pharmaceuticals Medical Information Services
Bayer HealthCare Pharmaceuticals Medical Information Services is a valuable support resource that can help answer medical questions and provide more information about Bayer HealthCare Pharmaceuticals marketed products, including Campath® (alemtuzumab).
1-888-84-BAYER (1-888-842-2937)
8:00am - 5:00pm PT (11:00 am - 8:00 pm ET)
Monday through Friday
Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).
WARNING: CYTOPENIAS, INFUSION REACTIONS, and INFECTIONS
Cytopenias: Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving Campath. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia [see WARNINGS AND PRECAUTIONS (5.1)].
Infusion Reactions: Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath for Grade 3 or 4 infusion reactions. Gradually escalate Campath to the recommended dose at the initiation of therapy and after interruption of therapy for 7 or more days [see DOSAGE AND ADMINISTRATION (2) and WARNINGS AND PRECAUTIONS (5.2)].
Infections: Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.3)].
The most commonly reported adverse reactions are infusion reactions fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections. See "Warnings and Precautions," and "Adverse Reactions" sections of full Prescribing Information.
Please see Full Prescribing Information (PDF).
